SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations

As of September 2021, there has been a total of 123,633 confirmed cases of pregnant women with SARS-CoV-2 infection in the US according to the CDC, with maternal death being 2.85 times more likely, pre-eclampsia 1.33 times more likely, preterm birth 1.47 times more likely, still birth 2.84 times mor...

Full description

Bibliographic Details
Main Authors: Patrida Rangchaikul, Vishwanath Venketaraman
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Infectious Disease Reports
Subjects:
Online Access:https://www.mdpi.com/2036-7449/13/4/91
_version_ 1827672205892255744
author Patrida Rangchaikul
Vishwanath Venketaraman
author_facet Patrida Rangchaikul
Vishwanath Venketaraman
author_sort Patrida Rangchaikul
collection DOAJ
description As of September 2021, there has been a total of 123,633 confirmed cases of pregnant women with SARS-CoV-2 infection in the US according to the CDC, with maternal death being 2.85 times more likely, pre-eclampsia 1.33 times more likely, preterm birth 1.47 times more likely, still birth 2.84 times more likely, and NICU admission 4.89 times more likely when compared to pregnant women without COVID-19 infection. In our literature review, we have identified eight key changes in the immunological functioning of the pregnant body that may predispose the pregnant patient to both a greater susceptibility to SARS-CoV-2, as well as a more severe disease course. Factors that may impede immune clearance of SARS-CoV-2 include decreased levels of natural killer (NK) cells, Th1 CD4+ T cells, plasmacytoid dendritic cells (pDC), a decreased phagocytic index of neutrophil granulocytes and monocytes, as well as the immunomodulatory properties of progesterone, which is elevated in pregnancy. Factors that may exacerbate SARS-CoV-2 morbidity through hyperinflammatory states include increases in the complement system, which are linked to greater lung injury, as well as increases in TLR-1 and TLR-7, which are known to bind to the virus, leading to increased proinflammatory cytokines such as IL-6 and TNF-α, which are already elevated in normal pregnant physiology. Other considerations include an increase in angiotensin converting enzyme 2 (ACE2) in the maternal circulation, leading to increased viral binding on the host cell, as well as increased IL-6 and decreased regulatory T cells in pre-eclampsia. We also focus on how the Delta variant has had a concerning impact on SARS-CoV-2 cases in pregnancy, with an increased case volume and proportion of ICU admissions among the infected expecting mothers. We propose that the effects of the Delta variant are due to a combination of (1) the Delta variant itself being more transmissible, contagious, and efficient at infecting host cells, (2) initial evidence pointing to the Delta variant causing a significantly greater viral load that accumulates more rapidly in the respiratory system, (3) the pregnancy state being more susceptible to SARS-CoV-2 infection, as discussed in-depth, and (4) the lower rates of vaccination in pregnant women compared to the general population. In the face of continually evolving strains and the relatively low awareness of COVID-19 vaccination for pregnant women, it is imperative that we continue to push for global vaccine equity.
first_indexed 2024-03-10T03:58:22Z
format Article
id doaj.art-46e039e0a96d42c5812faa798b90309b
institution Directory Open Access Journal
issn 2036-7449
language English
last_indexed 2024-03-10T03:58:22Z
publishDate 2021-11-01
publisher MDPI AG
record_format Article
series Infectious Disease Reports
spelling doaj.art-46e039e0a96d42c5812faa798b90309b2023-11-23T08:40:03ZengMDPI AGInfectious Disease Reports2036-74492021-11-01134993100810.3390/idr13040091SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant ConsiderationsPatrida Rangchaikul0Vishwanath Venketaraman1College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USACollege of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USAAs of September 2021, there has been a total of 123,633 confirmed cases of pregnant women with SARS-CoV-2 infection in the US according to the CDC, with maternal death being 2.85 times more likely, pre-eclampsia 1.33 times more likely, preterm birth 1.47 times more likely, still birth 2.84 times more likely, and NICU admission 4.89 times more likely when compared to pregnant women without COVID-19 infection. In our literature review, we have identified eight key changes in the immunological functioning of the pregnant body that may predispose the pregnant patient to both a greater susceptibility to SARS-CoV-2, as well as a more severe disease course. Factors that may impede immune clearance of SARS-CoV-2 include decreased levels of natural killer (NK) cells, Th1 CD4+ T cells, plasmacytoid dendritic cells (pDC), a decreased phagocytic index of neutrophil granulocytes and monocytes, as well as the immunomodulatory properties of progesterone, which is elevated in pregnancy. Factors that may exacerbate SARS-CoV-2 morbidity through hyperinflammatory states include increases in the complement system, which are linked to greater lung injury, as well as increases in TLR-1 and TLR-7, which are known to bind to the virus, leading to increased proinflammatory cytokines such as IL-6 and TNF-α, which are already elevated in normal pregnant physiology. Other considerations include an increase in angiotensin converting enzyme 2 (ACE2) in the maternal circulation, leading to increased viral binding on the host cell, as well as increased IL-6 and decreased regulatory T cells in pre-eclampsia. We also focus on how the Delta variant has had a concerning impact on SARS-CoV-2 cases in pregnancy, with an increased case volume and proportion of ICU admissions among the infected expecting mothers. We propose that the effects of the Delta variant are due to a combination of (1) the Delta variant itself being more transmissible, contagious, and efficient at infecting host cells, (2) initial evidence pointing to the Delta variant causing a significantly greater viral load that accumulates more rapidly in the respiratory system, (3) the pregnancy state being more susceptible to SARS-CoV-2 infection, as discussed in-depth, and (4) the lower rates of vaccination in pregnant women compared to the general population. In the face of continually evolving strains and the relatively low awareness of COVID-19 vaccination for pregnant women, it is imperative that we continue to push for global vaccine equity.https://www.mdpi.com/2036-7449/13/4/91SARS-CoV-2COVID-19delta variantpregnancyimmune response
spellingShingle Patrida Rangchaikul
Vishwanath Venketaraman
SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
Infectious Disease Reports
SARS-CoV-2
COVID-19
delta variant
pregnancy
immune response
title SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
title_full SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
title_fullStr SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
title_full_unstemmed SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
title_short SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations
title_sort sars cov 2 and the immune response in pregnancy with delta variant considerations
topic SARS-CoV-2
COVID-19
delta variant
pregnancy
immune response
url https://www.mdpi.com/2036-7449/13/4/91
work_keys_str_mv AT patridarangchaikul sarscov2andtheimmuneresponseinpregnancywithdeltavariantconsiderations
AT vishwanathvenketaraman sarscov2andtheimmuneresponseinpregnancywithdeltavariantconsiderations